Login to Your Account



Phase III Study Seeks to Boost Kiacta's Prospects

By Marie Powers


Thursday, December 16, 2010
Despite a bumpy road that includes two FDA approvable letters, the amyloid A (AA) amyloidosis drug candidate Kiacta (eprodisate) has been given another chance to prove itself through a confirmatory Phase III study that was initiated this week by Bellus Health, of Laval, Quebec, and its development partner Celtic Therapeutics LLLP.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription